rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Accuray Incorporated

ARAY · Nasdaq

Health CareMedical DevicesNot moving yet

ARAY stood above a rising 150-day average in 0 of the last 52 weekly readings. It is 49.2% below that average now. Medical Devices: 27% of its 181 stocks in an uptrend (−9 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 52
Industry in uptrend
27% -9 in 4 wk
Insider buys, 12 months
$288K
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
104 (-12)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 0 of 52 weeks.

17 Apr – 16 Oct
19%29%40%Apr 26Jun 26Jul 26Sep 26Oct 26

Medical Devices: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$259KNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months4
Sale orders, 12 months0
Buyers · sellers2 · 0
WhoDidSharesTraded
Steven F. MayerDirectorbought54,875at $0.562720 Feb 2026filed 23 Feb 2026
Steven F. MayerDirectorbought69,000at $0.530419 Feb 2026filed 20 Feb 2026
Steven F. MayerDirectorbought126,125at $0.532818 Feb 2026filed 20 Feb 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders104-12 on the quarter
New · exited24 · 37
Reported value$17.6M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
TCW GROUP INCadded · filed 3 Aug 202618,942,059$4.1M+3,474,107+22.5%
NEUBERGER BERMAN GROUP LLCadded · filed 13 Aug 20266,073,663$1.6M+218,599+3.7%
ARMISTICE CAPITAL, LLCadded · filed 14 Aug 20265,736,000$1.5M+100,000+1.8%
WEBER CAPITAL MANAGEMENT LLCreduced · filed 13 Aug 20264,932,706$1.3M-122,588−2.4%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 20264,437,800$1.1M+7,408+0.2%
BlackRock, Inc.reduced · filed 7 Aug 20263,266,185$842K-5,192,224−61.4%
AQR CAPITAL MANAGEMENT LLCadded · filed 14 Aug 20262,719,032$701K+2,101,555+340.3%
JANE STREET GROUP, LLCnew · filed 14 Aug 20262,139,720$552K+2,139,720
RENAISSANCE TECHNOLOGIES LLCreduced · filed 13 Aug 20262,065,284$532K-225,700−9.9%
DAFNA Capital Management LLCunchanged · filed 14 Aug 20261,680,508$433K00.0%
31 Mar 2023 – 30 Jun 2026
92106119Mar 23Dec 23Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

Richard A. Meier Company insiderDirector · last 5 Oct 20260 · 0
Ali Pervaiz Company insiderSVP Chief Financial Officer · last 23 Sep 20260 · 10
TCW GROUP INC Company insider10% owner · last 29 Jul 20260 · 0
Paul Michael Miele Company insiderSVP, Chief Commercial Officer · last 29 May 20260 · 0
Sandeep Chalke Company insiderSVP, Chief Commercial Officer · last 31 Mar 20260 · 3
Leonel Peralta Company insiderSVP, Chief Operations Officer · last 28 Feb 20260 · 0
Steven F. Mayer Company insiderDirector · last 20 Feb 20263 · 0
Byron C. Scott Company insiderDirector · last 31 Dec 20252 · 0
Beverly A. Huss Company insiderDirector · last 28 Nov 20250 · 0
Chan Galbato Company insiderDirector · last 28 Nov 20250 · 0
Grand Anne Bryce Le Company insiderDirector · last 28 Nov 20250 · 0
James M. Hindman Company insiderDirector · last 28 Nov 20250 · 0

Same industry

RCEL Avita MedicalLeading+100%
ATRC AtriCureLeading+49%
HAE HaemoneticsLeading+48%
HTFL HeartflowLeading+40%

Distance from each stock’s own 150-day average.

From its SEC filings

Profit per saleFY 2026 · to 30 Jun 202627.7%
Operating profit marginFY 2026 · to 30 Jun 2026-6.6%
Free cash flow marginFY 2026 · to 30 Jun 2026-3.2%
Return on capital employedFY 2026 · to 30 Jun 2026-10.5%
Debt to equityFY 2026 · to 30 Jun 20263.58×
Interest coverFY 2026 · to 30 Jun 2026-0.82×
Research spendFY 2026 · to 30 Jun 20269.4%
Share count trendFY 2026 · to 21 Aug 20260.0%
Cash and equivalentsFY 2026 · to 30 Jun 2026$40.6M
Free cash flowFY 2026 · to 30 Jun 2026−$12.8M

Analyst forecasts

No analyst forecasts yet.